Copyright
©The Author(s) 2021.
World J Diabetes. Nov 15, 2021; 12(11): 1832-1855
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1832
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1832
Table 1 Examples of antimicrobial activities of some antidiabetic drugs
| Antidiabetic drug | Antimicrobial activity | Proposed mechanism | Ref. |
| Metformin | Antibacterial | Activation of the AMPK-mediated phagocytosis and production of mROS | [170] |
| Disruption of the outer membrane permeability | [170] | ||
| Down regulation of the Q.S encoding genes and mitigate the bacterial virulence | [19,186] | ||
| Anti-TB | Increasing the production of β-defensin-2, -3 and -4 which diminish bacterial growth and multiplication | [178] | |
| Inhibition of mitochondrial complex-I which is analogous to mycobacterial NDH-I complex | [176] | ||
| Activation of T regulatory and CD8 memory T cells responses activity | [177] | ||
| Sitagliptin | Antibacterial | Downregulation of the Q.S encoding genes, occupy the Q.S receptors and diminish bacterial virulence | [18,19,186] |
| Anti-COVID-19 | Reduction of the inflammation intensity | [190,191] | |
| Targeting viral proteins | [192] | ||
| Binding to viral spikes | [193] | ||
| Antibiofilm | Targeting enzyme XPDAP, analogous to mammalian enzyme DPP IV | [187] | |
| Vildagliptin | Antibiofilm | Targeting enzyme XPDAP, analogous to DPP IV | [187] |
| Anti-amoebic | - | [188] | |
| Saxagliptin | Antibiofilm | Targeting enzyme XPDAP, analogous to DPP IV | [187] |
| Pioglitazone | Antibacterial | Increasing phagocytosis and production of reactive oxygen species in phagocytes | [197,198] |
| Tolbutamide | Antibacterial and antifungal | - | [205] |
| 2nd generation sulfonylureas | Antifungal | Inhibition of the NLRP3 inflammasome | [206] |
| Antibacterial | Prevention of inflammasome effector IL-1β | [207] | |
| Glimepiride | Anti-amoebic | - | [188] |
| Repaglinide | Anti-amoebic | - | [188] |
| Glucagon-like Peptide-1 | In HIV treatment | Reduction of HIV-associated metabolic adverse effects | [212] |
| α-glucosidase inhibitors | Antibacterial | Targeting bacterial glucosidase | [220] |
| Antiviral and anti-COVID | Alter glycosylation in viral life cycle | [221] |
- Citation: Hegazy WAH, Rajab AAH, Abu Lila AS, Abbas HA. Anti-diabetics and antimicrobials: Harmony of mutual interplay. World J Diabetes 2021; 12(11): 1832-1855
- URL: https://www.wjgnet.com/1948-9358/full/v12/i11/1832.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i11.1832
